This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.04.080v1 50/9/859    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by López, B. Articles by Díez, J. Search for Related Content PubMed Articles by López, B. Articles by Díez, J.

CLINICAL RESEARCH: HEART FAILURE

Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure

Begoña López, PhD^_*, Arantxa González, PhD^_*, Javier Beaumont, PhD^_*, Ramón Querejeta, MD, PhD, Mariano Larman, MD and Javier Díez, MD, PhD^_*,,_*

^_* Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
Division of Cardiology, Donostia University Hospital, San Sebastián, Spain
Division of Hemodynamics, Guipuzcoa Polyclinics, San Sebastián, Spain
Department of Cardiology and Cardiovascular Surgery, University Clinic, University of Navarra, Pamplona, Spain.

Manuscript received February 20, 2007; revised manuscript received April 25, 2007, accepted April 30, 2007.

^_* Reprint requests and correspondence: Dr. Javier Díez, Área de Ciencias Cardiovasculares, CIMA, Avenida Pío XII 55, 31008 Pamplona, Spain. (Email: jadimar{at}unav.es).

Objectives: This study sought to investigate whether torasemide inhibits the enzyme involved in the myocardial extracellular generation of collagen type I molecules (i.e., procollagen type I carboxy-terminal proteinase [PCP]).

Background: Torasemide has been reported to reduce myocardial fibrosis in patients with chronic heart failure (HF).

Methods: Chronic HF patients received either 10 to 20 mg/day oral torasemide (n = 11) or 20 to 40 mg/day oral furosemide (n = 11) in addition to their standard HF therapy. At baseline and after 8 months from randomization, right septal endomyocardial biopsies were obtained to analyze the expression of PCP by Western blot and the deposition of collagen fibers (collagen volume fraction [CVF]) with an automated image analysis system. The carboxy-terminal propeptide of procollagen type I (PICP) released as a result of the action of PCP on procollagen type I was measured in serum by radioimmunoassay.

Results: The ratio of PCP active form to PCP zymogen, an index of PCP activation, decreased (p < 0.05) in torasemide-treated patients and remained unchanged in furosemide-treated patients. A reduction (p < 0.01) in both CVF and PICP was observed in torasemide-treated but not in furosemide-treated patients. Changes in PCP activation were positively correlated (p < 0.001) with changes in CVF and changes in PICP in patients receiving torasemide.

Conclusions: These findings suggest the hypothesis that the ability of torasemide to reduce myocardial fibrosis in chronic HF patients is related to a decreased PCP activation. Further studies are required to ascertain whether PCP may represent a new target for antifibrotic strategies in chronic HF.

Abbreviations and Acronyms   CVF = collagen volume fraction   HF = heart failure   MMP = matrix metalloproteinase   mRNA = messenger ribonucleic acid   PCP = procollagen type I carboxy-terminal proteinase   PCPE = procollagen type I carboxy-terminal proteinase enhancer   PICP = carboxy-terminal propeptide of procollagen type I   TIMP = tissue inhibitor of matrix metalloproteinase

This article has been cited by other articles:

				A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez Biochemical markers of myocardial remodelling in hypertensive heart disease Cardiovasc Res, September 20, 2008; (2008) cvn235v2. [Abstract] [Full Text] [PDF]